Mereo BioPharma (MREO) Non-Current Debt (2017 - 2023)

Mereo BioPharma (MREO) has reported Non-Current Debt for 6 consecutive years, with $4.6 million the latest figure, recorded in Q2 2023.

• Quarterly Non-Current Debt changed N/A year-over-year to $4.6 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $4.6 million (changed N/A YoY) and the FY2021 annual result came in at $19.4 million, down 9.03% from the prior year.
• Non-Current Debt fell to $4.6 million in Q2 2023 per MREO's latest filing, from $19.4 million in the prior quarter.
• Over the last five years, Non-Current Debt for MREO reached as high as $25.1 million in Q2 2021 and fell as low as $4.6 million in Q2 2023.
• A 4-year average of $15.8 million and a median of $18.0 million in 2020 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2019 — Non-Current Debt tumbled 63.35% — and 2020, when it soared 208.54%.
• Year by year, Non-Current Debt stood at $6.9 million in 2019, then surged by 208.54% to $21.3 million in 2020, then retreated by 9.03% to $19.4 million in 2021, then slumped by 76.35% to $4.6 million in 2023.
• According to Business Quant data, Non-Current Debt over the past three periods registered $4.6 million, $19.4 million, and $25.1 million for Q2 2023, Q4 2021, and Q2 2021 respectively.